Published in Cold Spring Harb Perspect Med on April 01, 2012
HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature (2012) 3.63
HIV-1 assembly, budding, and maturation. Cold Spring Harb Perspect Med (2012) 3.17
HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc Natl Acad Sci U S A (2013) 1.85
HIV DNA integration. Cold Spring Harb Perspect Med (2012) 1.73
Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci Transl Med (2014) 1.49
Integrated analysis of residue coevolution and protein structures capture key protein sectors in HIV-1 proteins. PLoS One (2015) 1.42
Induction of IL-17 and nonclassical T-cell activation by HIV-Tat protein. Proc Natl Acad Sci U S A (2013) 1.41
HIV-1 reverse transcription. Cold Spring Harb Perspect Med (2012) 1.29
HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial. J Infect Dis (2014) 1.28
Discovery of novel small-molecule HIV-1 replication inhibitors that stabilize capsid complexes. Antimicrob Agents Chemother (2013) 1.18
LEDGINs inhibit late stage HIV-1 replication by modulating integrase multimerization in the virions. Retrovirology (2013) 1.17
HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design. Trends Microbiol (2012) 1.13
Cryo-electron microscopy of tubular arrays of HIV-1 Gag resolves structures essential for immature virus assembly. Proc Natl Acad Sci U S A (2014) 1.11
HIV pathogenesis: dynamics and genetics of viral populations and infected cells. Cold Spring Harb Perspect Med (2013) 1.11
Solution conformations of prototype foamy virus integrase and its stable synaptic complex with U5 viral DNA. Structure (2012) 1.07
Allosteric inhibition of human immunodeficiency virus integrase: late block during viral replication and abnormal multimerization involving specific protein domains. J Biol Chem (2014) 1.04
Long lasting control of viral rebound with a new drug ABX464 targeting Rev - mediated viral RNA biogenesis. Retrovirology (2015) 1.00
Differential gene expression in HIV-infected individuals following ART. Antiviral Res (2013) 0.94
Characterization of LEDGF/p75 genetic variants and association with HIV-1 disease progression. PLoS One (2012) 0.92
Effects of substitutions at the 4' and 2 positions on the bioactivity of 4'-ethynyl-2-fluoro-2'-deoxyadenosine. Antimicrob Agents Chemother (2013) 0.90
Treatment failure and drug resistance is more frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study period. AIDS (2013) 0.90
Approved Antiviral Drugs over the Past 50 Years. Clin Microbiol Rev (2016) 0.88
Aptamer-based therapeutics: new approaches to combat human viral diseases. Pharmaceuticals (Basel) (2013) 0.86
Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors. Viruses (2012) 0.86
Towards HIV-1 remission: potential roles for broadly neutralizing antibodies. J Clin Invest (2016) 0.85
Identification of highly conserved residues involved in inhibition of HIV-1 RNase H function by Diketo acid derivatives. Antimicrob Agents Chemother (2014) 0.85
In vitro antiviral activity of adenosine analog NITD008 against tick-borne flaviviruses. Antiviral Res (2016) 0.85
The role of matrix in HIV-1 envelope glycoprotein incorporation. Trends Microbiol (2014) 0.85
Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity. J Virol (2015) 0.84
Host Factors in Retroviral Integration and the Selection of Integration Target Sites. Microbiol Spectr (2014) 0.83
The high cost of fidelity. AIDS Res Hum Retroviruses (2014) 0.83
HIV-1 Resistance to the Capsid-Targeting Inhibitor PF74 Results in Altered Dependence on Host Factors Required for Virus Nuclear Entry. J Virol (2015) 0.82
Treatment with suboptimal doses of raltegravir leads to aberrant HIV-1 integrations. Proc Natl Acad Sci U S A (2013) 0.82
Particle infectivity of HIV-1 full-length genome infectious molecular clones in a subtype C heterosexual transmission pair following high fidelity amplification and unbiased cloning. Virology (2014) 0.82
Constellation pharmacology: a new paradigm for drug discovery. Annu Rev Pharmacol Toxicol (2015) 0.81
Innovation spread: lessons from HIV. Int J Qual Health Care (2013) 0.81
RNA interference approaches for treatment of HIV-1 infection. Genome Med (2015) 0.81
Confocal fluorescence microscopy: An ultra-sensitive tool used to evaluate intracellular antiretroviral nano-drug delivery in HeLa cells. AIP Adv (2015) 0.81
Roles of Capsid-Interacting Host Factors in Multimodal Inhibition of HIV-1 by PF74. J Virol (2016) 0.81
Vaccine-Induced Simian Immunodeficiency Virus-Specific CD8+ T-Cell Responses Focused on a Single Nef Epitope Select for Escape Variants Shortly after Infection. J Virol (2015) 0.80
Identification of myxobacteria-derived HIV inhibitors by a high-throughput two-step infectivity assay. Microb Cell Fact (2013) 0.78
Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother (2013) 0.78
Droplet microfluidics for kinetic studies of viral fusion. Biomicrofluidics (2016) 0.77
Effect of isoniazid preventive therapy on tuberculosis or death in persons with HIV: a retrospective cohort study. BMC Infect Dis (2015) 0.77
Persistence of frequently transmitted drug-resistant HIV-1 variants can be explained by high viral replication capacity. Retrovirology (2014) 0.77
High prevalence of PI resistance in patients failing second-line ART in Vietnam. J Antimicrob Chemother (2015) 0.77
The myxobacterial metabolite ratjadone A inhibits HIV infection by blocking the Rev/CRM1-mediated nuclear export pathway. Microb Cell Fact (2014) 0.77
Impact of Y181C and/or H221Y mutation patterns of HIV-1 reverse transcriptase on phenotypic resistance to available non-nucleoside and nucleoside inhibitors in China. BMC Infect Dis (2014) 0.77
COMMD1/Murr1 reinforces HIV-1 latent infection through IκB-α stabilization. J Virol (2014) 0.76
A mechanistic and structural investigation of modified derivatives of the diaryltriazine class of NNRTIs targeting HIV-1 reverse transcriptase. Biochim Biophys Acta (2014) 0.76
The Evolving Genotypic Profile of HIV-1 Mutations Related to Antiretroviral Treatment in the North Region of Brazil. Biomed Res Int (2015) 0.76
HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland. BMC Infect Dis (2012) 0.76
Characterization of VRC01, a potent and broadly neutralizing anti-HIV mAb, produced in transiently and stably transformed tobacco. Plant Biotechnol J (2013) 0.76
Effects of the W153L substitution in HIV reverse transcriptase on viral replication and drug resistance to multiple categories of reverse transcriptase inhibitors. Antimicrob Agents Chemother (2014) 0.76
Subtype-specific analysis of the K65R substitution in HIV-1 that confers hypersusceptibility to a novel nucleotide-competing reverse transcriptase inhibitor. Antimicrob Agents Chemother (2015) 0.76
Structural Basis for Inhibitor-Induced Aggregation of HIV Integrase. PLoS Biol (2016) 0.75
HIV Genome-Wide Protein Associations: a Review of 30 Years of Research. Microbiol Mol Biol Rev (2016) 0.75
Identifying enriched drug fragments as possible candidates for metabolic engineering. BMC Med Genomics (2016) 0.75
HIV Diagnosis and Treatment through Advanced Technologies. Front Public Health (2017) 0.75
Nelfinavir suppresses insulin signaling and nitric oxide production by human aortic endothelial cells: protective effects of thiazolidinediones. Ochsner J (2013) 0.75
SJP-L-5, a novel small-molecule compound, inhibits HIV-1 infection by blocking viral DNA nuclear entry. BMC Microbiol (2015) 0.75
Recent findings on the mechanisms involved in tenofovir resistance. Antivir Chem Chemother (2014) 0.75
Commentary: Questioning the HIV-AIDS Hypothesis: 30 Years of Dissent. Front Public Health (2015) 0.75
Herb-target interaction network analysis helps to disclose molecular mechanism of traditional Chinese medicine. Sci Rep (2016) 0.75
Longer duration of homelessness is associated with a lower likelihood of non-detectable plasma HIV-1 RNA viral load among people who use illicit drugs in a Canadian setting. AIDS Care (2016) 0.75
Drug resistant integrase mutants cause aberrant HIV integrations. Retrovirology (2016) 0.75
Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies. Int J Mol Sci (2016) 0.75
Coevolutionary Analysis Identifies Protein-Protein Interaction Sites between HIV-1 Reverse Transcriptase and Integrase. Virus Evol (2016) 0.75
Synthetic Peptides as Protein Mimics. Front Bioeng Biotechnol (2016) 0.75
Solution-phase parallel synthesis of acyclic nucleoside libraries of purine, pyrimidine, and triazole acetamides. ACS Comb Sci (2014) 0.75
Transient HIV-1 Gag-protease interactions revealed by paramagnetic NMR suggest origins of compensatory drug resistance mutations. Proc Natl Acad Sci U S A (2016) 0.75
Evaluation of novel protease inhibitors against darunavir-resistant variants of HIV type 1. FEBS Open Bio (2016) 0.75
Molecular dynamics modeling the synthetic and biological polymers interactions pre-studied via docking: anchors modified polyanions interference with the HIV-1 fusion mediator. J Comput Aided Mol Des (2014) 0.75
PharmGKB summary: Efavirenz pathway, pharmacokinetics. Pharmacogenet Genomics (2015) 0.75
The therapeutic potential of epigenetic manipulation during infectious diseases. Pharmacol Ther (2016) 0.75
A Highly Conserved Residue in HIV-1 Nef Alpha Helix 2 Modulates Protein Expression. mSphere (2016) 0.75
An Essential Role of INI1/hSNF5 Chromatin Remodeling Protein in HIV-1 Posttranscriptional Events and Gag/Gag-Pol Stability. J Virol (2016) 0.75
Identification of HIV Mutation as Diagnostic Biomarker through Next Generation Sequencing. J Clin Diagn Res (2016) 0.75
Expression, purification and identification of CtCVNH, a novel anti-HIV (Human Immunodeficiency Virus) protein from Ceratopteris thalictroides. Int J Mol Sci (2013) 0.75
Accessing biological actions of Ganoderma secondary metabolites by in silico profiling. Phytochemistry (2014) 0.75
Epistasis and Pleiotropy Affect the Modularity of the Genotype-Phenotype Map of Cross-Resistance in HIV-1. Mol Biol Evol (2016) 0.75
Recombinant rabbit single-chain antibodies bind to the catalytic and C-terminal domains of HIV-1 integrase protein and strongly inhibit HIV-1 replication. Biotechnol Appl Biochem (2012) 0.75
Cell-based gene therapy against HIV. Gene Ther (2015) 0.75
Does antiretroviral treatment change HIV-1 codon usage patterns in its genes: a preliminary bioinformatics study. AIDS Res Ther (2017) 0.75
The Membrane-Proximal Region of C-C Chemokine Receptor Type 5 Participates in the Infection of HIV-1. Front Immunol (2017) 0.75
Risk factors for delayed antiretroviral therapy initiation among HIV-seropositive patients. PLoS One (2017) 0.75
Chemical optimization of macrocyclic HIV-1 inactivators for improving potency and increasing the structural diversity at the triazole ring. Org Biomol Chem (2017) 0.75
Computational identification of novel entry inhibitor scaffolds mimicking primary receptor CD4 of HIV-1 gp120. J Mol Model (2017) 0.75
Prevalence of K65R in patients treated with tenofovir disoproxil fumarate: recommendations based on the Frankfurt HIV Cohort Study Resistance Database (FHCS-RD). Med Microbiol Immunol (2016) 0.75
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (1995) 34.97
The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature (1985) 30.47
Viral dynamics in human immunodeficiency virus type 1 infection. Nature (1995) 28.54
HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science (1996) 26.19
Identification of a major co-receptor for primary isolates of HIV-1. Nature (1996) 23.81
HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science (1996) 21.81
T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature (1985) 21.57
CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science (1996) 18.53
HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science (1995) 18.40
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science (1997) 18.10
Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science (1989) 15.19
Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science (1992) 14.70
A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell (1996) 14.64
Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother (2002) 13.91
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med (1999) 12.68
Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature (2007) 11.73
Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science (1998) 11.23
3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A (1985) 10.71
Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science (1997) 10.35
Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science (2010) 10.30
In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature (1995) 10.13
Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol (1995) 9.02
Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med (1998) 8.62
Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A (1986) 8.48
Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A (1994) 8.48
Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother (2005) 7.42
The molecular basis of the specific anti-influenza action of amantadine. EMBO J (1985) 7.08
ANTIVIRAL ACTIVITY OF 1-ADAMANTANAMINE (AMANTADINE). Science (1964) 6.72
Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol (2000) 6.71
Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides. Proc Natl Acad Sci U S A (1986) 6.63
Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med (1996) 6.14
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med (2003) 5.79
Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med (1996) 5.35
Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci U S A (1992) 5.19
Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother (1993) 5.08
Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science (1995) 4.98
Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature (2005) 4.71
Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol (1998) 4.48
Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci U S A (2002) 4.48
Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med (1996) 4.43
Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis (1992) 4.21
Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science (2009) 4.20
PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci U S A (2003) 4.03
Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J Mol Biol (1994) 3.85
A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res Hum Retroviruses (1993) 3.80
Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis (1998) 3.69
A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol Cell (1999) 3.67
Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol (1997) 3.64
HIV chemotherapy. Nature (2001) 3.63
Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science (1995) 3.60
A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS (2003) 3.60
Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry (1998) 3.59
Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob Agents Chemother (2000) 3.54
Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc Natl Acad Sci U S A (2002) 3.40
Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol (1996) 3.39
HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci U S A (2002) 3.28
HIV-1 assembly, budding, and maturation. Cold Spring Harb Perspect Med (2012) 3.17
A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl Acad Sci U S A (2000) 3.10
Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol (2001) 3.05
HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc Natl Acad Sci U S A (2000) 3.00
Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol (2006) 2.97
The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1995) 2.95
Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. J Virol (2001) 2.95
A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc Natl Acad Sci U S A (2003) 2.92
Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J Virol (1998) 2.92
In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir Ther (1999) 2.85
Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J Virol (2004) 2.80
HIV Restriction Factors and Mechanisms of Evasion. Cold Spring Harb Perspect Med (2012) 2.72
Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: implications of conformational changes for polymerization and inhibition mechanisms. Structure (1996) 2.69
Therapeutic efficacy of amantadine HCl and rimantadine HCl in naturally occurring influenza A2 respiratory illness in man. N Engl J Med (1969) 2.61
3'-Azido-3'-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase. Antimicrob Agents Chemother (1987) 2.60
Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother (1997) 2.57
A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc Natl Acad Sci U S A (2004) 2.55
Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor: high level of similarity of the active site with other viral integrases. J Mol Biol (1998) 2.49
Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: conserved helical interactions underlie the broad inhibitory activity of gp41 peptides. Proc Natl Acad Sci U S A (1998) 2.46
Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection. J Exp Med (2003) 2.37
Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol (2007) 2.33
Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations. J Theor Biol (1997) 2.30
Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med (1998) 2.27
Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr (2004) 2.21
Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol (2009) 2.19
Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc Natl Acad Sci U S A (2010) 2.16
Effects of (-)-2'-deoxy-3'-thiacytidine (3TC) 5'-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma. Antimicrob Agents Chemother (1992) 2.15
Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science (2004) 2.12
Anti-AIDS agents, 11. Betulinic acid and platanic acid as anti-HIV principles from Syzigium claviflorum, and the anti-HIV activity of structurally related triterpenoids. J Nat Prod (1994) 2.12
International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. J Acquir Immune Defic Syndr (2001) 2.12
Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. J Antimicrob Chemother (2003) 2.04
Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J Med Chem (2006) 2.03
Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility. J Virol (1996) 2.03
Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J Virol (2003) 1.97
Human immunodeficiency virus reverse transcriptase. General properties and its interactions with nucleoside triphosphate analogs. J Biol Chem (1987) 1.94
Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob Agents Chemother (2007) 1.91
Differential patterns of intracellular metabolism of 2',3'-didehydro-2',3'-dideoxythymidine and 3'-azido-2',3'-dideoxythymidine, two potent anti-human immunodeficiency virus compounds. J Biol Chem (1989) 1.89
Transcriptional and posttranscriptional regulation of HIV-1 gene expression. Cold Spring Harb Perspect Med (2012) 1.88
In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J Virol (2008) 1.84
Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J Virol (2008) 1.83
Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med (2008) 7.33
Genome-scale RNAi screen for host factors required for HIV replication. Cell Host Microbe (2008) 6.24
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med (2008) 5.58
Host cell factors in HIV replication: meta-analysis of genome-wide studies. PLoS Pathog (2009) 4.24
Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc Natl Acad Sci U S A (2002) 3.40
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J Med Chem (2008) 3.09
Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J Biol Chem (2003) 2.82
A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression. J Virol (2009) 2.30
Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. AIDS (2009) 2.28
Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS (2007) 2.27
c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. J Virol (2007) 2.24
A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties. Antimicrob Agents Chemother (2004) 1.94
Inhibition of HIV-1 ribonuclease H by a novel diketo acid, 4-[5-(benzoylamino)thien-2-yl]-2,4-dioxobutanoic acid. J Biol Chem (2002) 1.80
PD-1 blockade in rhesus macaques: impact on chronic infection and prophylactic vaccination. J Immunol (2009) 1.77
A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. Proc Natl Acad Sci U S A (2005) 1.74
Design and synthesis of 8-hydroxy-[1,6]naphthyridines as novel inhibitors of HIV-1 integrase in vitro and in infected cells. J Med Chem (2003) 1.55
MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother (2012) 1.48
Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor. J Virol (2010) 1.46
Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay. Antimicrob Agents Chemother (2005) 1.38
Probiotic/prebiotic supplementation of antiretrovirals improves gastrointestinal immunity in SIV-infected macaques. J Clin Invest (2013) 1.35
Structural basis for the inhibition of RNase H activity of HIV-1 reverse transcriptase by RNase H active site-directed inhibitors. J Virol (2010) 1.32
Altering expression levels of human immunodeficiency virus type 1 gp120-gp41 affects efficiency but not kinetics of cell-cell fusion. J Virol (2002) 1.29
Dissecting the effects of DNA polymerase and ribonuclease H inhibitor combinations on HIV-1 reverse-transcriptase activities. Biochemistry (2005) 1.25
Combined approaches for HIV cure. Curr Opin HIV AIDS (2013) 1.23
Structure, stereochemistry, and biological activity of integramycin, a novel hexacyclic natural product produced by Actinoplanes sp. that inhibits HIV-1 integrase. Org Lett (2002) 1.23
Analysis of low-frequency mutations associated with drug resistance to raltegravir before antiretroviral treatment. Antimicrob Agents Chemother (2010) 1.16
Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother (2009) 1.13
HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro. J Biol Chem (2006) 1.10
A potent and orally active HIV-1 integrase inhibitor. Bioorg Med Chem Lett (2006) 1.10
Potent and selective HIV-1 ribonuclease H inhibitors based on a 1-hydroxy-1,8-naphthyridin-2(1H)-one scaffold. Bioorg Med Chem Lett (2010) 1.06
Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium. Ann N Y Acad Sci (2011) 1.06
Distinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother (2010) 1.04
Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. Virology (2013) 1.02
Monitoring the development of non-nucleoside reverse transcriptase inhibitor-associated resistant HIV-1 using an electrochemiluminescence-based reverse transcriptase polymerase assay. Anal Biochem (2007) 0.95
Discovery of oxadiazoyl tertiary carbinamine inhibitors of beta-secretase (BACE-1). J Med Chem (2006) 0.95
In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother (2013) 0.93
Dihydroxypyridopyrazine-1,6-dione HIV-1 integrase inhibitors. Bioorg Med Chem Lett (2007) 0.92
A series of 5-(5,6)-dihydrouracil substituted 8-hydroxy-[1,6]naphthyridine-7-carboxylic acid 4-fluorobenzylamide inhibitors of HIV-1 integrase and viral replication in cells. Bioorg Med Chem Lett (2005) 0.91
Biochemical and cell-based assays for characterization of BACE-1 inhibitors. Anal Biochem (2005) 0.90
Isolation, structure, and HIV-1-integrase inhibitory activity of structurally diverse fungal metabolites. J Ind Microbiol Biotechnol (2004) 0.90
HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications. Drug Resist Updat (2004) 0.88
Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trial. Antivir Ther (2013) 0.88
Potential new therapies for the treatment of HIV-1 infection. Annu Rev Med (2002) 0.88
Four novel bis-(naphtho-gamma-pyrones) isolated from Fusarium species as inhibitors of HIV-1 integrase. Bioorg Med Chem Lett (2003) 0.87
Antiviral activity and in vitro mutation development pathways of MK-6186, a novel nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother (2012) 0.86
Beta-secretase cleavage at amino acid residue 34 in the amyloid beta peptide is dependent upon gamma-secretase activity. J Biol Chem (2003) 0.86
Gene expression profiling of rat liver reveals a mechanistic basis for ritonavir-induced hyperlipidemia. Genomics (2007) 0.85
Synthesis of 5-(1-H or 1-alkyl-5-oxopyrrolidin-3-yl)-8-hydroxy-[1,6]-naphthyridine-7-carboxamide inhibitors of HIV-1 integrase. Bioorg Med Chem Lett (2008) 0.84
Assessment of the susceptibility of mutant HIV-1 to antiviral agents. J Virol Methods (2010) 0.84
Novel mutations introduced at the beta-site of amyloid beta protein precursor enhance the production of amyloid beta peptide by BACE1 in vitro and in cells. J Alzheimers Dis (2005) 0.84
Dissecting Tn5 transposition using HIV-1 integrase diketoacid inhibitors. Biochemistry (2007) 0.83
A genotype 2b NS5B polymerase with novel substitutions supports replication of a chimeric HCV 1b:2b replicon containing a genotype 1b NS3-5A background. Antiviral Res (2005) 0.82
8-Hydroxy-3,4-dihydropyrrolo[1,2-a]pyrazine-1(2H)-one HIV-1 integrase inhibitors. Bioorg Med Chem Lett (2007) 0.81
Compounds that bind APP and inhibit Abeta processing in vitro suggest a novel approach to Alzheimer disease therapeutics. J Biol Chem (2005) 0.81
Design, synthesis, and SAR of macrocyclic tertiary carbinamine BACE-1 inhibitors. Bioorg Med Chem Lett (2007) 0.80
Scintillation proximity assays for mechanistic and pharmacological analyses of HIV-1 integration. Methods (2009) 0.80
Isolation, structure, absolute stereochemistry, and HIV-1 integrase inhibitory activity of integrasone, a novel fungal polyketide. J Nat Prod (2004) 0.80
Discovery of 2-Pyridinone Aminals: A Prodrug Strategy to Advance a Second Generation of HIV-1 Integrase Strand Transfer Inhibitors. J Med Chem (2015) 0.79
Isolation, structure, and HIV-1 integrase inhibitory activity of Cytosporic acid, a fungal metabolite produced by a Cytospora sp. J Nat Prod (2003) 0.79
A series of 5-aminosubstituted 4-fluorobenzyl-8-hydroxy-[1,6]naphthyridine-7-carboxamide HIV-1 integrase inhibitors. Bioorg Med Chem Lett (2006) 0.78
Integramides A and B, two novel non-ribosomal linear peptides containing nine C(alpha)-methyl amino acids produced by fungal fermentations that are inhibitors of HIV-1 integrase. Org Lett (2002) 0.78
10-Hydroxy-7,8-dihydropyrazino[1',2':1,5]pyrrolo[2,3-d]pyridazine-1,9(2H,6H)-diones: potent, orally bioavailable HIV-1 integrase strand-transfer inhibitors with activity against integrase mutants. Bioorg Med Chem Lett (2008) 0.77
Design and synthesis of substituted 4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-carboxamides, novel HIV-1 integrase inhibitors. Bioorg Med Chem Lett (2007) 0.77
Purification of untagged HIV-1 reverse transcriptase by affinity chromatography. Protein Expr Purif (2010) 0.77
Rapid P1 SAR of brain penetrant tertiary carbinamine derived BACE inhibitors. Bioorg Med Chem Lett (2010) 0.76
Total synthesis, characterization, and conformational analysis of the naturally occurring hexadecapeptide integramide A and a diastereomer. Chemistry (2010) 0.76
Pharmacodynamic analysis of a serine protease inhibitor, MK-4519, against hepatitis C virus using a novel in vitro pharmacodynamic system. Antimicrob Agents Chemother (2011) 0.76
Complete absolute configuration of integramide A, a natural, 16-mer peptide inhibitor of HIV-1 integrase, elucidated by total synthesis. Chembiochem (2009) 0.76
Isolation, structure and HIV-1 integrase inhibitory activity of exophillic acid, a novel fungal metabolite from Exophiala pisciphila. J Antibiot (Tokyo) (2003) 0.76
Triple Hyp→Pro replacement in integramide A, a peptaib inhibitor of HIV-1 integrase: Effect on conformation and bioactivity. Biopolymers (2011) 0.75
SAR of tertiary carbinamine derived BACE1 inhibitors: role of aspartate ligand amine pKa in enzyme inhibition. Bioorg Med Chem Lett (2010) 0.75
Correction to Discovery of 2-Pyridinone Aminals: A Prodrug Strategy to Advance a Second Generation of HIV-1 Integrase Strand Transfer Inhibitors. J Med Chem (2015) 0.75
Integracides: tetracyclic triterpenoid inhibitors of HIV-1 integrase produced by Fusarium sp. Bioorg Med Chem (2003) 0.75
Chemistry and structure-activity relationship of HIV-1 integrase inhibitor integracide B and related natural products. J Nat Prod (2003) 0.75